Myeloma in its current iteration and our approaches remains an incurable disease. Really when it comes down to it, the global unmet need is to find a cure. At a more pragmatic day-to-day level, the unmet need is dealing with people who have relapsed multiple times. We refer to patients with newly diagnosed myeloma as having high-risk or standard-risk by cytogenetics. We know that high-risk patients genetically do worse. Once you've relapsed beyond a few lines of therapy, or more specifically become relapsed and refractory to IMiDs, PIs, and monoclonal antibodies, you enter a realm of functional high-risk where even if you don't have a 17p or a 1q or a 4;14, the fact that there are more drugs behind you than in front of you means that you are functionally high-risk, and this is really the core area that we are currently focusing on a lot of our research efforts to maximize outcomes for patients who, at the current time, have very few options.